News Articles and Montana BioScience Alliance Newsletters
News, events, and SBIR/STTR Solicitations for May
A scientific team that includes University of Montana biologist Mark Grimes recently used artificial intelligence to better understand how protein groups in lung cancer cells regulate cell division and metabolism. The work may lead to greater understanding of lung cancer vulnerabilities and future anti-cancer therapies.
Viral clearance testing is a critical step in the development and production of biologics and other products that are derived from biological sources. GMP-compliant service provides the assurance that products have been thoroughly tested for the presence of viral contaminants, and that they are safe for use.
Scientists at the McLaughlin Institute are spearheading this patient registry which allows the Institute to enroll Montanans in potential clinical trials and research studies.
On January 12, 2023, the Montana High Tech Business Alliance and the Montana Bioscience Cluster Initiative co-hosted the webinar “Scaling Biotech Companies in Montana.” Panelists shared their insights into how companies can effectively plan for growth and how Montana can scale its biotech ecosystem.
The NIA is accepting applications for Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) funding. Learn more about these open opportunities. The next deadline to apply is January 5, 2024, unless otherwise noted.
The Senate has voted to confirm President Joe Biden’s pick to run the National Institutes of Health (NIH), Dr. Monica Bertagnolli, filling the director spot at the country’s top medical research agency after a vacancy of almost two years.
Updates from product development and small business programs
Are you working to develop an innovative cancer technology? Take a step forward in your commercialization journey through the newly released FY2024 SBIR Contract Solicitation! This funding opportunity aims to provide early-stage funding to small businesses that are developing cancer technologies in areas defined by the National Cancer Institute.
The U.S. Food and Drug Administration converted Leqembi (lecanemab-irmb), indicated to treat adult patients with Alzheimer’s Disease, to traditional approval following a determination that a confirmatory trial verified clinical benefit.